EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Lithium orotate: distinct compound or simply Li + after administration?

Tomas Hajek iD, Søren Munthe, Rasmus W Licht

The British Journal of Psychiatry · 2026

DOI: 10.1192/bjp.2026.10699 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The British Journal of Psychiatry, 2026. Verfasst von Tomas Hajek und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Dalhousie University, Halifax, Canada. Hauptthemen laut MEDLINE: Lithium Carbonate, Neuroprotective Agents, Lithium Compounds, Alzheimer Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The recent study by Aron et al about lithium deficiency and the onset of Alzheimer’s disease provides a valuable explanatory framework for understanding how very small doses of lithium, delivered via environmental exposure, can exert neuroprotective effects. It also contains results which will need to be reconciled with foundational chemistry and existing evidence and which could be potentially misleading. The suggestion that lithium orotate (LiO) exhibits benefits relative to the more traditionally used lithium carbonate (LiC) requires further scrutiny in light of the following arguments: (a) no study has demonstrated the presence of stable LiO in physiological fluids; (b) acid–base chemistry predicts that LiO will be largely protonated in the stomach, causing it to dissociate and be absorbed as Li + ; (c) experimental studies indicate that LiO and LiC have comparable pharmacokinetics after oral administration; and (d) previous research has shown that LiC also has neuroprotective effects, including at very low doses. Disproportionate focus on a specific lithium salt could have safety implications and may distract from answering fundamental questions about the effects of very low doses of lithium. More experiments are needed to provide evidence of a stable LiO complex in physiological fluids before this becomes the main form of lithium in future clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lithium CarbonateNeuroprotective AgentsLithium CompoundsAlzheimer DiseaseAntimanic AgentsLithiumHumans

Stichwörter der Autor:innen

Lithiumlithium carbonatelithium orotateneuroprotectionprevention

Substanzen

Lithium CarbonateNeuroprotective AgentsLithium CompoundsAntimanic AgentsLithium

Autor:innen und Institutionen

  • Department of Psychiatry, Dalhousie University, Halifax, Canada.
  • Retired Analytical Chemist, Aarhus, Denmark.
  • Psychiatry, Aalborg University Hospital, Aalborg, Denmark.

ORCID-Profile: Tomas Hajek

Zitieren

APA

Hajek, T., Munthe, S., & Licht, R. W. (2026). Lithium orotate: distinct compound or simply Li + after administration?. The British Journal of Psychiatry. https://doi.org/10.1192/bjp.2026.10699

Vancouver

Hajek T, Munthe S, Licht RW. Lithium orotate: distinct compound or simply Li + after administration?. The British Journal of Psychiatry. 2026. doi:10.1192/bjp.2026.10699

BibTeX
@article{Hajek2026,
  author = {Hajek, Tomas and Munthe, Søren and Licht, Rasmus W},
  title = {Lithium orotate: distinct compound or simply Li + after administration?},
  journal = {The British Journal of Psychiatry},
  year = {2026},
  doi = {10.1192/bjp.2026.10699}
}
Kostenlos starten →